View : 602 Download: 0
Reappraisal of MMR vaccines currently used in Korea
- Title
- Reappraisal of MMR vaccines currently used in Korea
- Authors
- Lee H.; Kim H.W.; Cho H.K.; Park E.A.; Choi K.M.; Kim K.-H.
- Ewha Authors
- 박은애; 김경효; 김한울
- SCOPUS Author ID
- 박은애; 김경효; 김한울
- Issue Date
- 2011
- Journal Title
- Pediatrics International
- ISSN
- 1328-8067
- Citation
- Pediatrics International vol. 53, no. 3, pp. 374 - 380
- Indexed
- SCIE; SCOPUS
- Document Type
- Article
- Abstract
- Background: Although MMR vaccine is widely used in Korea, there are limited studies on the currently used vaccines. We evaluated the immunogenicity and safety of MMR vaccines in Korean children. Methods: For first and second dose immunization, children aged 12-23 months and 4-6 years were enrolled. All subjects received a single dose of either Priorix™ (Glaxo Smithkline Biologicals, Rixensart, Belgium) or MMRII® (Merck & Co., Inc., West Point, PA, USA). Pre- and postvaccine sera were collected from all participants. Antibody levels were determined by ELISA (Enzygnost®; Dade Behring, Schwalbach, Germany). Safety monitoring included local adverse events for 5 days and systemic adverse events for 42 days following vaccination. Results: One hundred twenty-one subjects were enrolled in the 12-23 months age group and 39 in the 4-6 years age group. The seroconversion rate in the 12-23 months age group was 97.9-100.0% for measles, 85.1-88.9% for mumps and 100.0% for rubella. All children 4-6 years of age previously seronegative showed seroconversion for measles, mumps and rubella. Local adverse events were reported in 8.3-16.1% (12-23 months age) and 27.8-31.6% (4-6 years age), and 40.0-48.2% (12-23 months age) and 42.1-61.1% (4-6 years age) experienced at least more than 1 systemic adverse reaction. No vaccine-related serious adverse events were reported. Among the same age groups, there was no significant difference in adverse events between the two vaccines. Conclusion: The MMR vaccines are safe and show good immunogenic responses in children. These data will be invaluable when we introduce diverse vaccines in the following future. © 2011 Japan Pediatric Society.
- DOI
- 10.1111/j.1442-200X.2010.03244.x
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML